FENC Q1 2023 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M94.3% margin

Operating Income

-$5M-314.3% margin

Net Income

-$6M-360.9% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+9.3%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$22M

Total Liabilities

$29M

Stockholders' Equity

-$7M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	-$7,085	+22428.9%
Operating Income	-$5M	-$4M	-46.5%
Net Income	-$6M	-$4M	-61.8%